SEC 13F Intelligence

Managers / Q4 2021 · view latest →

Commodore Capital LP

CIK 0001831942 · 444 MADISON AVENUE, 35TH FLOOR, NEW YORK, NY, 10022 · 212-256-8600

Reported Value
$432M
Q4 2021
Positions
25
Filings on Record
25
2019–present window
Filed
Feb 14, 2022
original filing

Summary

Commodore Capital LP reported $432M in U.S.-listed holdings across 25 positions for Q4 2021.

Its largest position, OPHTEUR, represents 12.5% of the portfolio.

Compared with Q3 2021, the fund opened 3 new positions and exited 7.

Portfolio Metrics

Turnover
+24.2%
vs prior filed quarter
Top-10 Concentration
+72.7%
share of reported value
Largest Position
+12.5%
Iveric Bio
New / Exited
3 / 7
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $184MQ4 ’20Q1 ’21: $254MQ2 ’21: $290MQ3 ’21: $379MQ3 ’21Q4 ’21: $432MQ1 ’22: $448MQ2 ’22: $473MQ2 ’22Q3 ’22: $622MQ2 ’23: $890MQ3 ’23: $856MQ3 ’23Q4 ’23: $1.1BQ1 ’24: $1.5BQ2 ’24: $1.5BQ2 ’24Q3 ’24: $1.6BQ4 ’24: $1.4BQ1 ’25: $1.4BQ1 ’25Q2 ’25: $1.4BQ3 ’25: $2.0BQ4 ’25: $1.5BQ4 ’25Q1 ’26: $1.7Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 86.8%Other: 11.6%ADR: 1.6%
  • Common Stock · 86.8% · $375M
  • Other · 11.6% · $50M
  • ADR · 1.6% · $7M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BLUBELLUS HEALTH INC NEWNEW+3.12M3.12M+$25M$25M
1T7TRICIDA INCNEW+1.25M1.25M+$12M$12M
ALLKGUSDALLAKOS INCNEW+815.7K815.7K+$8M$8M
MERUS N VADDED+780.8K1.50M+$32M$48M
DRNAUSDDICERNA PHARMACEUTICALS INCSOLD OUT−1.29M0−$26M$0
KURAKURA ONCOLOGY INCSOLD OUT−999.4K0−$19M$0
TCE2CELLDEX THERAPEUTICS INC NEWSOLD OUT−248.2K0−$13M$0
IOVAIOVANCE BIOTHERAPEUTICS INCSOLD OUT−362.9K0−$9M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2021

25 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1OPHTEURIVERIC BIO INChistory →COM12.46%$54M3.22M
2MERUS N VCOM11.04%$48M1.50M
3ACRSACLARIS THERAPEUTICS INChistory →COM9.00%$39M2.67M
4XENEXENON PHARMACEUTICALS INChistory →COM7.89%$34M1.09M
5CYTKCYTOKINETICS INChistory →COM NEW7.44%$32M704.5K
6PTGXPROTAGONIST THERAPEUTICS INChistory →COM6.38%$28M805.6K
7BLUBELLUS HEALTH INC NEWhistory →COM NEW5.83%$25M3.12M
8COGTCOGENT BIOSCIENCES INChistory →COM4.53%$20M2.28M
9CYMABAY THERAPEUTICS INCCOM4.24%$18M5.42M
10VRDNVIRIDIAN THERAPEUTICS INChistory →COM3.88%$17M847.7K
11STSAUSDSATSUMA PHARMACEUTICALS INChistory →COM3.87%$17M3.71M
12VTGNUSDVISTAGEN THERAPEUTICS INChistory →COM NEW3.82%$17M8.46M
13CCCCC4 THERAPEUTICS INChistory →COM STK3.59%$15M481.1K
14CELCCELCUITY INChistory →COM2.81%$12M920.5K
151T7TRICIDA INChistory →COM2.76%$12M1.25M
16TNYATENAYA THERAPEUTICS INChistory →COM2.26%$10M513.9K
17ALLKGUSDALLAKOS INChistory →COM1.85%$8M815.7K
184XC1KALVISTA PHARMACEUTICALS INCCOM0.96%$4M312.6K
19KRON1USDKRONOS BIO INCCOM0.94%$4M298.8K
20DYNDYNE THERAPEUTICS INCCOM0.84%$4M305.1K
21IVAINVENTIVA SAADS0.83%$4M262.7K
22GNCAQGENOCEA BIOSCIENCES INCCOM NEW0.83%$4M3.08M
23MREOMEREO BIOPHARMA GROUP PLCADS0.72%$3M1.95M
24PMVPPMV PHARMACEUTICALS INCCOM0.67%$3M125.0K
25BCLS ACQUISITION CORPCOM CL A0.57%$2M250.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.7B36May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$1.5B33Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$2.0B37Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.4B33Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.4B31May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.4B31Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.6B36Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.5B35Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$1.5B39May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.1B32Feb 14, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$856M30Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$890M26Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review32May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review35Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$622M30Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$473M24Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$448M27May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$432M25Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$379M29Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$290M29Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$254M31May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$184M28Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.